Therapy News and Research

RSS

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

Mice born without a certain enzyme can resist the normal effects of a heart attack and retain nearly normal function in the heart's ventricles and still-oxygenated heart tissue, according to a study by researchers at Duke University Medical Center.

30 Mar 2009

South Carolina audit finds inadequacies in Medicaid transportation service program

The South Carolina Legislative Audit Council, the investigative arm of the General Assembly, on Wednesday released an audit report finding that the state might have improperly managed the Medicaid transportation program, the Columbia State reports.

30 Mar 2009

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Afinitor oral tablets (everolimus) for the treatment of patients with advanced kidney cancer whose disease has progressed after treatment with other cancer therapies.

30 Mar 2009

The spread of drug resistant HIV-1

Drug-resistant forms of HIV can be spread between individuals who have not received anti-retroviral treatment, according to Professor Deenan Pillay from University College, London and the Health Protection Agency, speaking at the Society for General Microbiology meeting at Harrogate.

30 Mar 2009

Targeted drug therapy prevents exercise-induced arrhythmias

A 12-year-old Dutch boy - bedridden for three years because of an inherited cardiac arrhythmia syndrome - can now join his friends on the soccer field thanks to a discovery made by Vanderbilt University Medical Center researchers.

30 Mar 2009

Corthera's Relaxin in acute heart failure shows promising results

Corthera Inc. has announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, placebo-controlled international study, demonstrated promising efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure (AHF).

30 Mar 2009

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema - the swelling of brain tissue - and not from any direct anti-tumor effect, according to a study from Massachusetts General Hospital (MGH) researchers.

30 Mar 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients

Medgenics has announced that the latest, encouraging results of the Company's ongoing EPODURE Biopump Phase I/II Clinical Trial were presented at the 45th Conference of the Israeli Society of Nephrology and Hypertension, in Israel on March 27, 2009.

29 Mar 2009

Improved predictive value of biomarkers in HF makes earlier diagnosis and better management possible

With an ever ageing population and more people surviving a heart attack, heart failure is now the world's most prevalent chronic cardiovascular disease.

29 Mar 2009

Improved predictive value of biomarkers in heart failure now makes earlier diagnosis and better management possible

With an ever ageing population and more people surviving a heart attack, heart failure is now the world's most prevalent chronic cardiovascular disease.

29 Mar 2009

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

ARCA biopharma, Inc. has announced that data from the pivotal Phase 3 BEST trial of Gencaro (bucindolol hydrochloride) in patients with advanced chronic heart failure (CHF) was presented at the American College of Cardiology 58 th Annual Scientific Session being held March 29-31, 2009 in Orlando, Florida.

29 Mar 2009

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

Findings published in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo.

29 Mar 2009

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

Results from a new sub-analysis of the JUPITER study show that patients who attained a dual treatment target of LDL-C <70mg/dL and high-sensitivity C-reactive protein (hsCRP) <2mg/L with CRESTOR (rosuvastatin) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%, p=0.033) among men and women with low to normal cholesterol levels and elevated hsCRP.

29 Mar 2009

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p=0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

29 Mar 2009

A comparative analysis of four beta blocker trials

ARCA biopharma, Inc. has announced that a comparative analysis of primary endpoint data from four beta blocker trials was presented at the American College of Cardiology 58th Annual Scientific Session being held March 29-31, 2009.

29 Mar 2009

AHF delegation meets with WHO and UNAIDS, urges action on access to AIDS treatment, testing and condoms

An international delegation from AIDS Healthcare Foundation (AHF), the largest AIDS group in the US which currently provides medical care to more than 98,000 individuals in 21 countries worldwide in the US, Africa, Latin America/Caribbean and Asia, met today with officials from the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) to call for action and partnership to vastly increase global access to HIV/AIDS treatment, testing and condoms.

29 Mar 2009

Discovery of protein that reactivates latent herpes simplex virus

Research in Public Library of Science (PLoS) Pathogens appears to solve a long standing medical mystery by identifying a viral protein, VP16, as the molecular key that prompts herpes simplex virus (HSV) to exit latency and cause recurrent disease.

29 Mar 2009

St. Jude Medical announces first European patient implants of Libra deep brain stimulation systems for Parkinson’s Disease

St. Jude Medical, Inc. has announced the first patient implants of its Libra deep brain stimulation (DBS) system for treating the symptoms of Parkinson's disease, a progressive neurological disorder that affects a person's control over his or her movements and speech.

29 Mar 2009

Positive phase 3 uveitis trial results for voclosporin

Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.

29 Mar 2009

Therapy News and Research

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

South Carolina audit finds inadequacies in Medicaid transportation service program

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

The spread of drug resistant HIV-1

Targeted drug therapy prevents exercise-induced arrhythmias

Corthera's Relaxin in acute heart failure shows promising results

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients

Improved predictive value of biomarkers in HF makes earlier diagnosis and better management possible

Improved predictive value of biomarkers in heart failure now makes earlier diagnosis and better management possible

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A comparative analysis of four beta blocker trials

AHF delegation meets with WHO and UNAIDS, urges action on access to AIDS treatment, testing and condoms

Discovery of protein that reactivates latent herpes simplex virus

St. Jude Medical announces first European patient implants of Libra deep brain stimulation systems for Parkinson’s Disease

Positive phase 3 uveitis trial results for voclosporin

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News